<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042861</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069478</org_study_id>
    <secondary_id>NCI-NAVY-01-04</secondary_id>
    <secondary_id>NCI-5535</secondary_id>
    <secondary_id>NCI-02-C-0222</secondary_id>
    <nct_id>NCT00042861</nct_id>
    <nct_alias>NCT00039637</nct_alias>
  </id_info>
  <brief_title>UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors</brief_title>
  <official_title>A Phase I Pharmacologic Trial Of Infusional UCN-01 Given With A Weekly Schedule Of 5-Fluorouracil And Leucovorin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining UCN-01, fluorouracil, and&#xD;
      leucovorin in treating patients who have metastatic or unresectable solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of fluorouracil when given in combination with&#xD;
           UCN-01 and leucovorin calcium in patients with metastatic or unresectable solid tumors.&#xD;
&#xD;
        -  Determine the clinical toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of these drugs in these patients.&#xD;
&#xD;
        -  Correlate, if possible, the pharmacokinetics of these drugs with clinical toxicity in&#xD;
           these patients.&#xD;
&#xD;
        -  Assess the pharmacodynamic effects of these drugs in these patients.&#xD;
&#xD;
        -  Assess any clinical activity of this regimen in patients with measurable disease.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of fluorouracil (5-FU).&#xD;
&#xD;
      Patients receive leucovorin calcium (CF) IV over 2 hours and 5-FU IV (at the midpoint of CF&#xD;
      administration) on day 1, followed by UCN-01 IV over 36-72 hours, on weeks 1-3. Courses&#xD;
      repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3&#xD;
      or 2 of 6 patients experience dose-limiting toxicity. The recommended phase II dose (RPIID)&#xD;
      is defined as the dose preceding the MTD. At least 6 additional patients are treated at the&#xD;
      RPIID.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study within 16 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-hydroxystaurosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor that is metastatic or unresectable and for which&#xD;
             no standard curative or palliative measures exist or are effective&#xD;
&#xD;
          -  No brain metastases or primary CNS malignancy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No known active coronary artery disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary dysfunction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of unusually severe and/or prolonged toxicity during prior therapy with&#xD;
             fluorouracil (5-FU) or 5-FU prodrugs&#xD;
&#xD;
          -  No diabetes mellitus requiring insulin or oral hypoglycemic therapy&#xD;
&#xD;
          -  No ongoing or active infection requiring IV antibiotics&#xD;
&#xD;
          -  No other serious concurrent medical illness that would preclude study&#xD;
&#xD;
          -  No psychiatric illness or social situations that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  No concurrent cytokines during the first course of therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior pulmonary or mediastinal radiation exceeding 40 Gy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent cimetidine&#xD;
&#xD;
          -  No concurrent sorivudine or brivudine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean L. Grem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>7-hydroxystaurosporine</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

